Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
Excellent safety, tolerability and pharmacokinetic profile
Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay
Phase 2 trial planned in CAPS patients to efficiently establish clinical proof of concept
Clinical update in Q3 from Phase 1 trial of VTX958, our oral, selective allosteric TYK2 inhibitor
Excerpt from the Press Release:
ENCINITAS, Calif., June 29, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a multi-asset, clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a peripheral NLRP3 inhibitor, and the first of two product candidates from its NLRP3 portfolio.
“The Phase 1 study demonstrated an excellent exposure and safety profile and evidence of dose-dependent target engagement and pharmacodynamic activity,” said Bill Sandborn, MD, President and Chief Medical Officer. “Inhibition of the NLRP3 inflammasome is emerging as a potent anti-inflammatory mechanism with therapeutic potential in a broad range of indications with high unmet medical need. We look forward to sharing additional details from this trial and a broader discussion of the clinical opportunities available with VTX2735 at an investor event later this year.”
The VTX2735 Phase 1 SAD/MAD clinical trial was a two-part, randomized, double-blind, placebo controlled, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses. The study enrolled 72 adult healthy volunteers in SAD cohorts up to 200 mg and MAD cohorts up to 200 mg daily for 14 days. VTX2735 was well-tolerated across all dose cohorts and all subjects completed the trial.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?